University of Leipzig and SiSaf partner over Bio-Courier targeted miRNA

pharmafile | March 27, 2023 | News story | Medical Communications  

SiSaf, an RNA delivery and therapeutics company, has announced a collaboration with the University of Leipzig to develop Bio-Courier targeted micro interfering RNAs (miRNA) for cancer treatments.


The aim is to create a replacement therapy combining both miR506-3p and miR24-3p using SiSaf’s Bio-Courier drug delivery platform and the University of Leipzig’s expertise in miRNA targeting and therapeutics approaches for cancer.


miRNAs are involved in the regulation of various physiological and pathological processes. Aberrant downregulation of miRNAs in tumours may result in pathological overexpression of oncogenes, which would make miRNA replacement a viable treatment. The Bio-Courier drug delivery platform uses elemental silicone to optimise lipid nanoparticle technology for RNA therapeutics, meaning the platform can offer improved RNA loading capacity and protection with efficient transfection and controlled release.


Under the agreement, SiSaf has the exclusive option to acquire a worldwide licence to a patent by the University.


Professor Achim Aigner, clinical pharmacology in the faculty of medicine at Leipzig University, said: “Due to their parallel, selective effects on multiple defined targets, miRNAs offer exceptional opportunities for the development of novel drugs that show enhanced efficacy while avoiding tumour cell resistance. Also, miRNAs act on messenger RNAs rather than proteins, thus providing innovative treatment avenues. We are delighted to further pursue our promising miRNA candidates towards possible translation into the clinic, by teaming up with SiSaf and its extensive expertise.”


Dr Suzanne Saffie-Siebert, chief executive officer of SiSaf, stated: “We are delighted to be working with Professor Aigner and his team to explore opportunities to deliver miRNA’s using our Bio-Courier platform. We have already applied our technology to improve siRNA and mRNA delivery, with great success. This is our first collaboration in micro interfering RNA delivery and expands our programs into a new area of RNA therapy … Pancreatic cancer is an area of high unmet need, and we are encouraged by Professor Aigner’s research and the potential to develop miRNA-based replacement therapies to improve outcomes for patients.”


James Spargo

Related Content

No items found

Latest content